{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibbfzo4eosq326jftwe4244ohbe3aukdbb5u3xlyn736gt3m4acfe",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjwqxx3upz32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidiavrj7bwnixq6jbqb7u4ygujvvqjkp6rb2mgrwf6oph3bm4knp4"
    },
    "mimeType": "image/jpeg",
    "size": 454185
  },
  "path": "/news/2026-04-antibody-drug-conjugate-clinical-benefit.html",
  "publishedAt": "2026-04-20T10:00:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.",
  "title": "New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer"
}